Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 14, 2022

Primary Completion Date

August 31, 2024

Study Completion Date

August 31, 2025

Conditions
Pancreas Cancer
Interventions
DRUG

Pemigatinib 4.5 MG

"Pemigatinib 4.5 mg tablets taken 3 times per day \[daily dose of 13.5 mg (3 tablets)\] for 14 consecutive days followed by 7 days off medication in 21-day cycles~Doses will be self-administered at home. Participants will be instructed to take study medication at the same time each day, with or without food."

Trial Locations (1)

85258

HonorHealth Research Institute, Scottsdale

Sponsors
All Listed Sponsors
collaborator

Incyte Corporation

INDUSTRY

lead

HonorHealth Research Institute

OTHER